Aurora Spine Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASAPF research report →
Price Chart
About the company
Established in 2013 and headquartered in Toronto, Canada, Aurora Spine Corporation, through its subsidiary Aurora Spine, Inc. , specializes in the development and distribution of advanced, minimally invasive spinal fusion systems and devices within the Canadian market. The company offers a comprehensive portfolio of products designed to address various spinal conditions, particularly degenerative disc diseases.
- CEO
- Trent J. Northcutt
- IPO
- 2013
- Employees
- 18
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on ASAPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.04M
- P/E
- -3.63
- PEG
- 0.04
- P/S
- 0.25
- P/B
- 1.55
- EV/EBITDA
- 27.78
- Div Yield
- 0.00%
- Gross Margin
- 41.85%
- Op Margin
- -4.98%
- Net Margin
- -6.95%
- ROE
- -34.32%
- ROIC
- -13.75%
Latest fiscal year · YoY change
- Revenue
- $18.69M+6.4%
- Gross Profit
- $4.51M-57.5%
- Op Income
- $-335,761
- Net Income
- $-743,918+22.1%
- EPS
- $-0.01+22.8%
- OCF Growth
- +3.2%
- FCF Growth
- -15.3%
- 52W High
- $0.24
- 52W Low
- $0.05
- 50D MA
- $0.08
- 200D MA
- $0.15
- Beta
- -0.56
- RSI (14)
- 32
- Avg Volume
- 19.01K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Aurora Spine posted a solid 2024 with 21% revenue growth, higher gross margin, and its first full year of positive EBITDAC, while management highlighted new product launches and a push toward cash-flow positivity in 2025.· April 29, 2025
- 2024 revenue rose 21% to $17.56 million, driven by more procedures and stronger adoption of proprietary products like SiLO-TFX and ZIP.
- Gross margin improved to 60.5% for the year from 56.5% in 2023, helped by a better product mix and more sales into ambulatory surgery centers.
- SiLO-TFX revenue grew 135% in 2024, and ZIP-51 sales increased 69%, reinforcing the company’s proprietary-product growth story.
- Management said Aurora ended Q4 with $0.826 million in cash and does not need to raise capital currently.
- The company expects 2025 to be focused on profitability and cash flow, while also advancing AERO, DEXA-L, and continued training-led expansion.
Total revenue was $4.7 million in Q4 2024, up 16.3% from $4.04 million in Q4 2023. Full-year 2024 revenue was $17.56 million, up from $14.52 million in 2023, an increase of about 21%. Gross margin was 57.8% in Q4 2024 versus 56.7% a year ago, and 60.5% for full-year 2024 versus 56.5% in 2023. Operating expenses were $3.22 million in Q4 2024 and $11.438 million for the year; EBITDAC was negative $0.32 million in Q4 and positive $0.28 million for the full year, compared with positive $0.11 million and negative $0.31 million respectively in 2023. Net loss was $0.653 million in Q4 2024 and $1.003 million for the full year, versus $0.85 million and $1.68 million in 2023. Management did not provide formal next-quarter or full-year numerical guidance, but said it expects Q1 2025 to be the best first quarter in company history, full-year revenue growth of at least 20%, and profitability on an annual basis; Trent Northcutt also said the focus for 2025 is to be full cash-flow positive.
Trent Northcutt struck an upbeat tone and framed 2024 as a milestone year, citing 21% revenue growth, margin improvement, and the first full year of positive EBITDAC. He emphasized that growth is being driven by proprietary products, especially SiLO-TFX, ZIP, and DEXA, plus the newly built internal sales force, now 14 people. He also highlighted AERO as a major future catalyst, saying the market opportunity is larger than SiLO and that early doctor feedback has been positive, while stressing the company wants to keep investing but still hit profitability and cash-flow goals.
Chad Clouse focused on the financial improvement profile: Q4 revenue of $4.7 million, full-year revenue of $17.56 million, gross margin expanding to 60.5% for the year, and EBITDAC turning positive for the year at $0.28 million. He said Q4 EBITDAC was hurt by a negative $0.154 million fair-value accounting impact on a note receivable, and that operating expenses rose because of training, society meetings, and the expanded direct sales team. On the balance sheet, he said Aurora ended with $0.826 million in cash, collections improved, receivables were lowered to below $0.5 million, and the capital structure is sufficient for this year’s budget.
Analysts asked where sales growth is coming from, and management pointed to a mix of new doctor adoption, regional sales expansion, and product mix across SiLO-TFX, ZIP-51, Osteo Onyx, and DEXA-C. On margins, Trent said direct sales are more attractive than distribution because distributors can take 25% to 35% commissions, but the company will still use distributors where needed. Questions on AERO focused on rollout timing, training, and market size; management said the first five alpha sites will do a small number of implants, a beta phase is expected after that, and the facet market could represent more than 4 million annual injections. On capital, Trent said Aurora is not actively looking to raise money.
The call showed real momentum in Aurora’s core products, with SiLO-TFX up 135% and ZIP-51 up 69%, while gross margin expanded meaningfully for the year. Management also sounded confident that 2025 can bring at least 20% revenue growth, continued product launches, and full cash-flow positivity, with AERO potentially opening a much larger addressable market.
Aurora is still small and not yet consistently cash-generative, ending Q4 with only $0.826 million in cash and posting a quarterly net loss of $0.653 million. Growth also depends on continued training, physician adoption, and execution of a direct-sales strategy, while management acknowledged seasonality and that margins can vary with product mix, distribution commissions, and training spend.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.6%
- Shares Outstanding
- 78.09M
- Float Shares
- 59.00M
Our ASAPF coverage
Recent articles, reports, and earnings notes.
No research on ASAPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASAPF report →Aurora Spine Announces Publication of REFINE Study's 12-Month Results in the International Journal of Spine Surgery
newsfilecorp.com · Oct 22
Aurora Spine Corporation Announces Amendment to Loan from Insider
newsfilecorp.com · Sep 29
Aurora Spine Corporation Announces Second Quarter FY26 Financial Results
newsfilecorp.com · Aug 27
Aurora Spine Announces Settlement of Arbitration, New Patent License Agreement for SI Joint Product and Increase in Funding from Insider
newsfilecorp.com · Aug 14
Aurora Spine and CornerLoc Announce Strategic Commercial Alliance to Expand Minimally Invasive Spine and SI Joint Solutions Nationwide
newsfilecorp.com · Jul 16
Aurora Spine Grants Stock Options
feeds.newsfilecorp.com · Jun 9
Aurora Spine Corporation (ASG:CA) Q1 2026 Earnings Call Transcript
seekingalpha.com · May 28
Aurora Spine Corporation Announces First Quarter FY26 Financial Results
globenewswire.com · May 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.